Alto Neuroscience, Inc. (ANRO) — Institutional Holders, Q2 2026 (page 2)

114 institutional investment managers reported a ANRO position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $777.6M. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 101 to 114. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

ANRO 13F holders ranked 101–114 of 114

Institutional investors reporting a position in Alto Neuroscience, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Accent Capital Management#101 · 366 sh$9.7KNew
NISA INVESTMENT ADVISORS#102 · 338 sh$8.9K0.0%
Aster Capital Management (DIFC) Ltd#103 · 135 sh$3.6KNew
Optiver Holding B.V.#104 · 112 sh$3.0K+2700.0%
FEDERATED HERMES#105 · 110 sh$2.9K-83.2%
Sterling Capital Management#106 · 92 sh$2.4KNew
Cornerstone Financial Management#107 · 69 sh$1.8K0.0%
US BANCORP \DE\#108 · 39 sh$1.0K-64.5%
SBI Securities , Ltd.#109 · 12 sh$317.000.0%
Farther Finance Advisors#110 · 11 sh$290.000.0%
GAMMA Investing#111 · 8 sh$211.00New
SRS Capital Advisors#112 · 5 sh$132.000.0%
OSAIC#113 · 3 sh$79.000.0%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#114 · 361 sh—New

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.